When state lawmakers introduce new bills about psychedelic access in 2026, most will specifically name veterans with PTSD or traumatic brain injury as the target group—and more will mention ibogaine than psilocybin or MDMA. This matters because it shows where political energy is moving: away from broad public access and toward a narrow, bipartisan coalition around veteran treatment.
The political coalition around veteran PTSD and TBI is bipartisan and well-organized. MAPS MDMA setback and ongoing FDA ibogaine scrutiny have redirected advocacy energy toward state right-to-try pathways for veterans specifically. Ibogaine's TBI data from the Stanford/USNORTHCOM trial gives it a clinical story MDMA currently lacks. Falsifiable by counting introduced bills.